Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
32
PRME Quote, Financials, Valuation and Earnings
Last price:
$3.62
Seasonality move
:
-21.37%
Day range:
$3.61 - $3.85
52-week range:
$1.11 - $6.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
82.09x
P/B ratio:
4.06x
Volume:
16.4M
Avg. volume:
4.2M
1-year change:
30.47%
Market cap:
$657.1M
Revenue:
$3M
EPS (TTM):
-$1.48
Analysts' Opinion
-
Consensus RatingPrime Medicine, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.46, Prime Medicine, Inc. has an estimated upside of 77.59% from its current price of $3.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.25 representing 100% downside risk from its current price of $3.64.
Fair Value
-
According to the consensus of 10 analysts, Prime Medicine, Inc. has 77.59% upside to fair value with a price target of $6.46 per share.
PRME vs. S&P 500
-
Over the past 5 trading days, Prime Medicine, Inc. has underperformed the S&P 500 by -11.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Prime Medicine, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Prime Medicine, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Prime Medicine, Inc. reported revenues of $1.2M.
Earnings Growth
-
Prime Medicine, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Prime Medicine, Inc. reported earnings per share of -$0.32.
Enterprise value:
561.9M
EV / Invested capital:
--
Price / LTM sales:
82.09x
EV / EBIT:
--
EV / Revenue:
94.01x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-4.88x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.2M
Return On Assets:
-54.36%
Net Income Margin (TTM):
-3301.64%
Return On Equity:
-146.77%
Return On Invested Capital:
-88.63%
Operating Margin:
-4405.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $800K | $6M | $209K | $1.2M | |
| Gross Profit | -$16.5M | -$4.9M | -$1.2M | -$1.3M | -$656K | |
| Operating Income | -$175.4M | -$212.8M | -$204M | -$54.2M | -$54M | |
| EBITDA | -$158.9M | -$207.1M | -$196.8M | -$52.7M | -$52.1M | |
| Diluted EPS | -$1.88 | -$2.01 | -$1.48 | -$0.44 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $300.4M | $148.8M | $184.5M | $246.1M | $231.4M | |
| Total Assets | $315.2M | $215.3M | $239.1M | $332.8M | $385M | |
| Current Liabilities | $9.5M | $22.2M | $39.4M | $37.9M | $35M | |
| Total Liabilities | $13.8M | $42.6M | $45.2M | $143.3M | $223.2M | |
| Total Equity | $301.4M | $172.7M | $194M | $189.5M | $161.8M | |
| Total Debt | $4.3M | $19.9M | $5.8M | $36.8M | $110.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$152.3M | -$183M | -$109.1M | -$25.9M | -$35M | |
| Cash From Investing | -$36.3M | $61.5M | -$88.8M | $50.3M | -$92.1M | |
| Cash From Financing | $184.5M | $196.1M | $151M | $38.5M | $144.8M | |
| Free Cash Flow | -$164M | -$190.3M | -$115.1M | -$27.2M | -$35.3M | |
PRME
Sector
Market Cap
$657.1M
$27.9M
Price % of 52-Week High
52.45%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-15.44%
-1.49%
1-Year Price Total Return
30.47%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.95
200-day SMA
Buy
Level
$3.24
Bollinger Bands (100)
Sell
Level
3.42 - 5.26
Chaikin Money Flow
Sell
Level
-18M
20-day SMA
Sell
Level
$3.83
Relative Strength Index (RSI14)
Sell
Level
43.01
ADX Line
Sell
Level
15.76
Williams %R
Neutral
Level
-67.2414
50-day SMA
Sell
Level
$4.33
MACD (12, 26)
Buy
Level
0.69
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
10.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2123)
Sell
CA Score
(Annual)
Level (-3.3923)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (3.7768)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, PRME has received 6 Buy ratings 4 Hold ratings, and 0 Sell ratings. The PRME average analyst price target in the past 3 months is $6.46.
-
Where Will Prime Medicine, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Prime Medicine, Inc. share price will rise to $6.46 per share over the next 12 months.
-
What Do Analysts Say About Prime Medicine, Inc.?
Analysts are divided on their view about Prime Medicine, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prime Medicine, Inc. is a Sell and believe this share price will drop from its current level to $4.25.
-
What Is Prime Medicine, Inc.'s Price Target?
The price target for Prime Medicine, Inc. over the next 1-year time period is forecast to be $6.46 according to 10 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is PRME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Prime Medicine, Inc. is a Buy. 6 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRME?
You can purchase shares of Prime Medicine, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prime Medicine, Inc. shares.
-
What Is The Prime Medicine, Inc. Share Price Today?
Prime Medicine, Inc. was last trading at $3.62 per share. This represents the most recent stock quote for Prime Medicine, Inc.. Yesterday, Prime Medicine, Inc. closed at $3.64 per share.
-
How To Buy Prime Medicine, Inc. Stock Online?
In order to purchase Prime Medicine, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PRME Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PRME
Sector
P/E ratio
--
23.85x
PEG ratio
-0.06x
-0.01x
P/B ratio
4.06x
1.81x
Price / LTM sales
82.09x
1.58x
Growth Metrics
PRME
Sector
Revenue growth
486.12%
4.62%
Earnings growth
28.12%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.24
-$0.21
Profitability
PRME
Sector
Profitability FY 2024
-$3.1M
$3.6M
Return on invested capital
-88.63%
-31.87%
Return on assets
-54.36%
-28.18%
Return on equity
-146.77%
-37.63%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Feb
27
Estimated Next Earnings Date
Feb
6
Balance Sheet
PRME
Sector
Total cash
$213.3M
$26.4M
Short term investments
$8M
$25.7M
Total assets
$490.1M
$76.9M
Long term debt
$110.4M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
